Overexpression of EagI potassium channels in clinical tumours

2006 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Overexpression of EagI potassium channels in clinical tumours​
Hemmerlein, B.; Weseloh, R. M.; Mello de Queiroz, F.; Knötgen, H.; Sanchez, A.; Rubio, M. E. & Martin, S. et al.​ (2006) 
Molecular Cancer5 art. 41​.​ DOI: https://doi.org/10.1186/1476-4598-5-41 

Documents & Media

2006-hemmerlein.pdf2.02 MBAdobe PDF

License

Published Version

Special user license Goescholar License

Details

Authors
Hemmerlein, Bernhard; Weseloh, Rüdiger M.; Mello de Queiroz, Fernanda; Knötgen, Hendrik; Sanchez, Araceli; Rubio, Maria E.; Martin, Sabine; Schliephacke, Tessa; Jenke, Marc; Radzun, Heinz-Joachim ; Stühmer, Walter ; Pardo, Luis A.
Abstract
Background: Certain types of potassium channels (known as Eag1, KCNHO1, Kv10.1) are associated with the production of tumours in patients and in animals. We have now studied the expression pattern of the Eag1 channel in a large range of normal and tumour tissues from different collections utilising molecular biological and immunohistochemical techniques. Results: The use of reverse transcription real-time PCR and specifically generated monoclonal anti-Eag1 antibodies showed that expression of the channel is normally limited to specific areas of the brain and to restricted cell populations throughout the body. Tumour samples, however, showed a significant overexpression of the channel with high frequency (up to 80% depending on the tissue source) regardless of the detection method (staining with either one of the antibodies, or detection of Eag1 RNA). Conclusion: Inhibition of Eag1 expression in tumour cell lines reduced cell proliferation. Eag1 may therefore represent a promising target for the tailored treatment of human tumours. Furthermore, as normal cells expressing Eag1 are either protected by the blood-brain barrier or represent the terminal stage of normal differentiation, Eag1 based therapies could produce only minor side effects.
Issue Date
2006
Journal
Molecular Cancer 
ISSN
1476-4598
Language
English

Reference

Citations


Social Media